Full Press Release Details
FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review.
BIIB
FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
Key Takeaway: FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis